|
|
||||||||
1
Childrens Hospital, University of Cologne, Josef-Stelzmann Strasse 9, 50924 Cologne, Germany.
2
Research Institute for Child Nutrition, Heinstück 11, 44225 Dortmund, Germany.
3
Childrens Hospital, University of Giessen, Germany and Lilly Deutschland GmbH, Saalburgstrasse 153, 61350 Bad Homburg, Germany.
aAddress correspondence to this author at: Genetics Unit, Shriners Hospital for Children, 1529 Cedar Ave., Montreal, Qc H3G 1A6 Canada. Fax 1-514-8425581; e-mail frauch{at}shriners.mcgill.ca.
Background: In children and adolescents, markers of bone and collagen metabolism reflect the dynamics of skeletal growth and development. The aim of this study was to assess the relationship of the urinary collagen markers deoxypyridinoline (DPD) and hydroxylysine (Hyl) and its glycosides [galactosyl-Hyl (Gal-Hyl) and glucosyl-Gal-Hyl] with growth.
Methods: Urine samples from 240 apparently healthy children and adolescents (619 years; 124 girls) and from 51 prepubertal children with growth hormone (GH) deficiency (314 years; 14 girls) were analyzed. Urinary Hyl and its glycosides were quantified by HPLC, and DPD was assessed by chemiluminescence assay. Urinary concentrations of all markers were related to urinary creatinine.
Results: Multiple regression analysis revealed that only age and height velocity were independently associated with these markers in healthy children. In GH-deficient patients, the urinary excretion of both analytes after 4 weeks of GH therapy correlated significantly with the height increase during the first treatment year (r = 0.79 for Gal-Hyl; r = 0.70 for DPD; P <0.001 each). In a multivariate linear regression model using Gal-Hyl concentrations at 4 weeks, baseline concentrations of insulin-like growth factor 1 and height velocity after 3 months accounted for 80% of the variability in height gain during the first treatment year. A model using DPD concentrations at 4 weeks, in place of Gal-Hyl concentrations, as well as baseline concentrations of insulin-like growth factor 1 and height velocity after 3 months accounted for 83% of the variability.
Conclusions: These urinary bone and collagen markers give some early indication of growth response, but the prediction of an individual marker is too imprecise to serve as a basis for clinical decisions. Markers of bone and collagen metabolism might be more useful as components of multivariate growth prediction models.
The following articles in journals at HighWire Press have cited this article:
![]() |
M. E. Kraenzlin, C. A. Kraenzlin, C. Meier, C. Giunta, and B. Steinmann Automated HPLC Assay for Urinary Collagen Cross-links: Effect of Age, Menopause, and Metabolic Bone Diseases Clin. Chem., September 1, 2008; 54(9): 1546 - 1553. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rauchenzauner, A. Schmid, P. Heinz-Erian, K. Kapelari, G. Falkensammer, A. Griesmacher, G. Finkenstedt, and W. Hogler Sex- and Age-Specific Reference Curves for Serum Markers of Bone Turnover in Healthy Children from 2 Months to 18 Years J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 443 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Westhoff, R. Krauspe, A. E. Kalke, D. Hermsen, B. Kowall, R. Willers, and U. Schneider Urinary excretion of deoxypyridinoline in Perthes' disease: A PROSPECTIVE, CONTROLLED COMPARATIVE STUDY IN 83 CHILDREN J Bone Joint Surg Br, July 1, 2006; 88-B(7): 967 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Land, W F Blum, A Stabrey, and E Schoenau Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency Eur. J. Endocrinol., May 1, 2005; 152(5): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |